| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Human Growth Hormone | 30 | 2023 | 683 | 8.960 |
Why?
|
| Pituitary ACTH Hypersecretion | 18 | 2023 | 176 | 8.490 |
Why?
|
| Acromegaly | 22 | 2023 | 347 | 8.070 |
Why?
|
| Pituitary Neoplasms | 23 | 2023 | 1346 | 6.550 |
Why?
|
| Hypopituitarism | 17 | 2023 | 254 | 5.220 |
Why?
|
| Adenoma | 19 | 2023 | 2174 | 4.610 |
Why?
|
| Hyperprolactinemia | 8 | 2022 | 129 | 3.360 |
Why?
|
| Cushing Syndrome | 7 | 2023 | 249 | 3.220 |
Why?
|
| Growth Hormone | 13 | 2023 | 703 | 2.200 |
Why?
|
| Growth Hormone-Secreting Pituitary Adenoma | 5 | 2023 | 45 | 2.170 |
Why?
|
| Dwarfism, Pituitary | 3 | 2023 | 46 | 2.050 |
Why?
|
| Pituitary Diseases | 5 | 2023 | 141 | 1.900 |
Why?
|
| Prolactinoma | 3 | 2023 | 113 | 1.760 |
Why?
|
| Pituitary Gland | 10 | 2023 | 665 | 1.730 |
Why?
|
| Diabetes Insipidus | 7 | 2019 | 151 | 1.680 |
Why?
|
| Hydrocortisone | 9 | 2023 | 1826 | 1.650 |
Why?
|
| Adrenal Glands | 4 | 2021 | 547 | 1.580 |
Why?
|
| Bone Density | 12 | 2021 | 3468 | 1.490 |
Why?
|
| Adrenocorticotropic Hormone | 11 | 2023 | 648 | 1.430 |
Why?
|
| Receptors, Somatotropin | 3 | 2020 | 76 | 1.330 |
Why?
|
| Somatostatin | 9 | 2020 | 459 | 1.240 |
Why?
|
| Insulin-Like Growth Factor I | 15 | 2023 | 2014 | 1.200 |
Why?
|
| Craniopharyngioma | 2 | 2021 | 281 | 1.060 |
Why?
|
| Pituitary Hormones | 10 | 2013 | 183 | 1.010 |
Why?
|
| Endocrinology | 4 | 2020 | 443 | 0.950 |
Why?
|
| Peptide Hormones | 4 | 2006 | 134 | 0.900 |
Why?
|
| Saliva | 2 | 2018 | 809 | 0.860 |
Why?
|
| Dopamine Agonists | 4 | 2022 | 355 | 0.840 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2023 | 740 | 0.820 |
Why?
|
| Adrenal Insufficiency | 5 | 2022 | 184 | 0.810 |
Why?
|
| Peptides, Cyclic | 4 | 2020 | 401 | 0.810 |
Why?
|
| Thyrotropin | 3 | 2020 | 850 | 0.800 |
Why?
|
| Bone and Bones | 4 | 2021 | 2575 | 0.780 |
Why?
|
| Hypothalamic Hormones | 8 | 2004 | 147 | 0.730 |
Why?
|
| Receptors, Somatostatin | 2 | 2020 | 129 | 0.710 |
Why?
|
| Enzyme Inhibitors | 2 | 2023 | 3800 | 0.710 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2018 | 302 | 0.700 |
Why?
|
| Melanins | 8 | 2004 | 289 | 0.680 |
Why?
|
| ACTH-Secreting Pituitary Adenoma | 2 | 2020 | 62 | 0.670 |
Why?
|
| Mitotane | 4 | 2021 | 18 | 0.670 |
Why?
|
| Frozen Sections | 1 | 2019 | 155 | 0.670 |
Why?
|
| Hormone Replacement Therapy | 5 | 2017 | 744 | 0.660 |
Why?
|
| Octreotide | 2 | 2020 | 145 | 0.650 |
Why?
|
| Brain Injuries | 3 | 2015 | 2025 | 0.640 |
Why?
|
| Neurotransmitter Agents | 3 | 2018 | 647 | 0.640 |
Why?
|
| Leptin | 11 | 2004 | 1599 | 0.630 |
Why?
|
| Antimetabolites | 1 | 2018 | 125 | 0.610 |
Why?
|
| Humans | 131 | 2023 | 744220 | 0.590 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 2727 | 0.580 |
Why?
|
| Hypothalamus | 5 | 2013 | 1063 | 0.550 |
Why?
|
| Cytodiagnosis | 1 | 2019 | 435 | 0.530 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 738 | 0.500 |
Why?
|
| Adult | 61 | 2023 | 214035 | 0.490 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2004 | 859 | 0.490 |
Why?
|
| Radius | 1 | 2017 | 422 | 0.480 |
Why?
|
| Metyrapone | 3 | 2021 | 23 | 0.480 |
Why?
|
| Hormones | 1 | 2018 | 887 | 0.470 |
Why?
|
| Ketoconazole | 3 | 2021 | 95 | 0.470 |
Why?
|
| Bromocriptine | 2 | 2023 | 111 | 0.440 |
Why?
|
| Monitoring, Intraoperative | 1 | 2019 | 953 | 0.430 |
Why?
|
| Osteoporotic Fractures | 1 | 2017 | 401 | 0.430 |
Why?
|
| Quality of Life | 9 | 2023 | 12805 | 0.420 |
Why?
|
| Cranial Irradiation | 1 | 2015 | 401 | 0.420 |
Why?
|
| Endocrine System | 1 | 2013 | 113 | 0.420 |
Why?
|
| Nelson Syndrome | 1 | 2011 | 20 | 0.420 |
Why?
|
| Prader-Willi Syndrome | 1 | 2012 | 79 | 0.410 |
Why?
|
| Middle Aged | 53 | 2021 | 213367 | 0.400 |
Why?
|
| Water-Electrolyte Imbalance | 2 | 2013 | 113 | 0.400 |
Why?
|
| Osteoporosis | 2 | 2017 | 1580 | 0.400 |
Why?
|
| Adrenal Cortex | 1 | 2011 | 140 | 0.390 |
Why?
|
| Etomidate | 3 | 2021 | 190 | 0.390 |
Why?
|
| Male | 76 | 2022 | 350027 | 0.390 |
Why?
|
| Neuropeptides | 5 | 2001 | 942 | 0.390 |
Why?
|
| Mifepristone | 3 | 2020 | 150 | 0.380 |
Why?
|
| Pituitary Gland, Anterior | 1 | 2010 | 177 | 0.370 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 2011 | 238 | 0.370 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2018 | 1509 | 0.360 |
Why?
|
| Obesity | 13 | 2008 | 12742 | 0.360 |
Why?
|
| Retrospective Studies | 24 | 2022 | 77426 | 0.350 |
Why?
|
| Female | 59 | 2023 | 380197 | 0.340 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2008 | 1018 | 0.340 |
Why?
|
| Tumor Burden | 3 | 2022 | 1914 | 0.340 |
Why?
|
| Adrenoleukodystrophy | 2 | 2022 | 123 | 0.340 |
Why?
|
| Aneurysm | 1 | 2012 | 339 | 0.320 |
Why?
|
| Mortality | 1 | 2020 | 2864 | 0.320 |
Why?
|
| Hormone Antagonists | 2 | 2022 | 107 | 0.320 |
Why?
|
| Thirst | 1 | 2008 | 38 | 0.310 |
Why?
|
| Prolactin | 2 | 2022 | 669 | 0.310 |
Why?
|
| Disease Management | 1 | 2018 | 2458 | 0.310 |
Why?
|
| Carotid Arteries | 1 | 2012 | 952 | 0.300 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2011 | 711 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 9230 | 0.280 |
Why?
|
| Carcinoma, Medullary | 1 | 2007 | 123 | 0.280 |
Why?
|
| Obesity, Morbid | 3 | 2015 | 1213 | 0.280 |
Why?
|
| Thyroid Gland | 1 | 2013 | 1172 | 0.270 |
Why?
|
| Oxytocin | 2 | 2020 | 394 | 0.260 |
Why?
|
| Radiosurgery | 1 | 2015 | 1328 | 0.260 |
Why?
|
| Carotid Artery Diseases | 1 | 2012 | 882 | 0.260 |
Why?
|
| Databases, Factual | 4 | 2014 | 7730 | 0.260 |
Why?
|
| Remission Induction | 3 | 2015 | 2389 | 0.250 |
Why?
|
| Thinness | 3 | 2004 | 479 | 0.250 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2008 | 2072 | 0.250 |
Why?
|
| Aged | 29 | 2020 | 163253 | 0.240 |
Why?
|
| Neuropeptide Y | 4 | 2001 | 200 | 0.240 |
Why?
|
| Dizziness | 1 | 2007 | 251 | 0.240 |
Why?
|
| Societies, Medical | 2 | 2016 | 3741 | 0.240 |
Why?
|
| Hyperaldosteronism | 1 | 2007 | 240 | 0.240 |
Why?
|
| Wrestling | 1 | 2003 | 18 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 6535 | 0.230 |
Why?
|
| Adrenalectomy | 3 | 2011 | 342 | 0.230 |
Why?
|
| Body Mass Index | 10 | 2020 | 12718 | 0.230 |
Why?
|
| Lumbar Vertebrae | 1 | 2013 | 1848 | 0.230 |
Why?
|
| Anorexia | 1 | 2004 | 159 | 0.230 |
Why?
|
| Hypothyroidism | 2 | 2015 | 659 | 0.230 |
Why?
|
| Hypothalamic Area, Lateral | 2 | 2001 | 104 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2021 | 35423 | 0.220 |
Why?
|
| Arginine | 2 | 2020 | 944 | 0.220 |
Why?
|
| Thyroid Neoplasms | 2 | 2007 | 2281 | 0.210 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2002 | 101 | 0.210 |
Why?
|
| ROC Curve | 2 | 2020 | 3527 | 0.210 |
Why?
|
| Ghrelin | 4 | 2006 | 266 | 0.210 |
Why?
|
| Young Adult | 15 | 2020 | 56436 | 0.210 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 12355 | 0.200 |
Why?
|
| Internationality | 2 | 2021 | 1003 | 0.200 |
Why?
|
| Glucose Tolerance Test | 5 | 2020 | 1150 | 0.200 |
Why?
|
| Disease Progression | 1 | 2018 | 13280 | 0.200 |
Why?
|
| Diastole | 1 | 2004 | 791 | 0.200 |
Why?
|
| Prognosis | 9 | 2020 | 29050 | 0.200 |
Why?
|
| Iopamidol | 1 | 2001 | 191 | 0.190 |
Why?
|
| Diagnosis, Differential | 4 | 2023 | 12961 | 0.190 |
Why?
|
| Postoperative Period | 4 | 2020 | 1841 | 0.180 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2020 | 19 | 0.180 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2020 | 46 | 0.180 |
Why?
|
| Treatment Outcome | 13 | 2020 | 63119 | 0.180 |
Why?
|
| Melanocyte-Stimulating Hormones | 1 | 1999 | 25 | 0.180 |
Why?
|
| Chemokine CCL2 | 1 | 2002 | 617 | 0.180 |
Why?
|
| Fasting | 2 | 2003 | 1591 | 0.180 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2001 | 129 | 0.180 |
Why?
|
| Eating | 4 | 2001 | 1538 | 0.180 |
Why?
|
| Water-Electrolyte Balance | 2 | 2013 | 346 | 0.180 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2012 | 187 | 0.170 |
Why?
|
| Cold Temperature | 1 | 2003 | 774 | 0.170 |
Why?
|
| Carcinoma, Papillary | 1 | 2004 | 783 | 0.170 |
Why?
|
| Fractures, Bone | 3 | 2017 | 1947 | 0.170 |
Why?
|
| Sarcoidosis | 1 | 2004 | 505 | 0.170 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2000 | 88 | 0.170 |
Why?
|
| Histiocytosis | 1 | 1998 | 39 | 0.160 |
Why?
|
| Premenopause | 2 | 2021 | 1033 | 0.160 |
Why?
|
| Neurotensin | 1 | 1998 | 61 | 0.160 |
Why?
|
| alpha-MSH | 1 | 1998 | 68 | 0.160 |
Why?
|
| Intraoperative Period | 1 | 2019 | 520 | 0.160 |
Why?
|
| Off-Label Use | 1 | 2020 | 169 | 0.160 |
Why?
|
| Absorptiometry, Photon | 2 | 2017 | 1725 | 0.160 |
Why?
|
| Vasopressins | 1 | 2020 | 370 | 0.160 |
Why?
|
| Bone Density Conservation Agents | 1 | 2005 | 773 | 0.160 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2000 | 162 | 0.160 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2020 | 160 | 0.160 |
Why?
|
| Glucagon | 2 | 2016 | 533 | 0.150 |
Why?
|
| Hyperparathyroidism | 1 | 1999 | 339 | 0.150 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1998 | 246 | 0.150 |
Why?
|
| Diphtheria Toxin | 1 | 1998 | 255 | 0.150 |
Why?
|
| Homeostasis | 4 | 2008 | 3339 | 0.150 |
Why?
|
| Pelvic Bones | 1 | 2020 | 265 | 0.150 |
Why?
|
| Aorta | 1 | 2005 | 2061 | 0.150 |
Why?
|
| Museums | 1 | 1997 | 19 | 0.150 |
Why?
|
| RNA, Messenger | 7 | 2013 | 13036 | 0.150 |
Why?
|
| Age of Onset | 3 | 2016 | 3270 | 0.150 |
Why?
|
| Parathyroidectomy | 1 | 1999 | 235 | 0.150 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 1998 | 271 | 0.150 |
Why?
|
| Circadian Rhythm | 3 | 2018 | 2624 | 0.150 |
Why?
|
| Radiography | 3 | 2013 | 7022 | 0.140 |
Why?
|
| Protein Precursors | 1 | 2001 | 1154 | 0.140 |
Why?
|
| Appetite | 1 | 1998 | 243 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2003 | 1854 | 0.140 |
Why?
|
| Estradiol | 1 | 2004 | 2020 | 0.140 |
Why?
|
| Endocrine System Diseases | 1 | 1998 | 248 | 0.140 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2016 | 45 | 0.140 |
Why?
|
| Cardiovascular System | 1 | 2004 | 832 | 0.140 |
Why?
|
| Brain Hemorrhage, Traumatic | 1 | 2015 | 18 | 0.140 |
Why?
|
| Proteins | 6 | 1998 | 6101 | 0.130 |
Why?
|
| Insulin | 5 | 2020 | 6583 | 0.130 |
Why?
|
| Insulin Infusion Systems | 1 | 1997 | 212 | 0.130 |
Why?
|
| Goals | 1 | 2021 | 706 | 0.130 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 1344 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 9960 | 0.130 |
Why?
|
| Ventricular Function, Left | 2 | 2005 | 3669 | 0.130 |
Why?
|
| Gastric Bypass | 1 | 2003 | 812 | 0.120 |
Why?
|
| Consensus | 2 | 2022 | 2958 | 0.120 |
Why?
|
| Animals | 21 | 2018 | 168788 | 0.120 |
Why?
|
| Imidazoles | 1 | 2021 | 1206 | 0.120 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2016 | 440 | 0.120 |
Why?
|
| Age Factors | 6 | 2020 | 18367 | 0.120 |
Why?
|
| Child | 8 | 2023 | 77679 | 0.120 |
Why?
|
| Risk Factors | 9 | 2020 | 72280 | 0.120 |
Why?
|
| Neoplasms | 1 | 2023 | 21672 | 0.120 |
Why?
|
| Nocturnal Enuresis | 1 | 2013 | 12 | 0.120 |
Why?
|
| Hyperthyroidism | 1 | 2016 | 295 | 0.120 |
Why?
|
| Polyuria | 1 | 2013 | 39 | 0.110 |
Why?
|
| Logistic Models | 2 | 2020 | 13409 | 0.110 |
Why?
|
| Metabolome | 1 | 2020 | 895 | 0.110 |
Why?
|
| Recombinant Proteins | 2 | 2014 | 6612 | 0.110 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 417 | 0.110 |
Why?
|
| Cross-Sectional Studies | 10 | 2022 | 25043 | 0.110 |
Why?
|
| Petrosal Sinus Sampling | 1 | 2012 | 23 | 0.110 |
Why?
|
| Adipose Tissue, Brown | 1 | 1998 | 754 | 0.110 |
Why?
|
| Adipose Tissue | 2 | 2004 | 3278 | 0.110 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 2204 | 0.110 |
Why?
|
| Time Factors | 6 | 2020 | 40063 | 0.100 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 941 | 0.100 |
Why?
|
| Cerebellum | 2 | 1998 | 1490 | 0.100 |
Why?
|
| Weight Loss | 1 | 2003 | 2622 | 0.100 |
Why?
|
| Impulsive Behavior | 1 | 2014 | 316 | 0.100 |
Why?
|
| Bayes Theorem | 1 | 2020 | 2309 | 0.100 |
Why?
|
| Case-Control Studies | 6 | 2020 | 21752 | 0.100 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2012 | 89 | 0.100 |
Why?
|
| Blood Pressure | 2 | 2005 | 8551 | 0.100 |
Why?
|
| Endpoint Determination | 2 | 2019 | 601 | 0.100 |
Why?
|
| Gene Expression Regulation | 2 | 2001 | 12075 | 0.100 |
Why?
|
| Femur Neck | 1 | 2013 | 309 | 0.100 |
Why?
|
| Stimulation, Chemical | 1 | 2011 | 326 | 0.100 |
Why?
|
| Glucose | 1 | 2003 | 4396 | 0.100 |
Why?
|
| Receptors, Pituitary Hormone | 2 | 2001 | 29 | 0.100 |
Why?
|
| Stress, Physiological | 1 | 1998 | 1404 | 0.100 |
Why?
|
| Adolescent | 10 | 2019 | 85759 | 0.090 |
Why?
|
| Adrenal Gland Diseases | 1 | 2011 | 138 | 0.090 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 644 | 0.090 |
Why?
|
| Lipids | 2 | 2020 | 3305 | 0.090 |
Why?
|
| Hypothalamo-Hypophyseal System | 3 | 2019 | 703 | 0.090 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 390 | 0.090 |
Why?
|
| Dizocilpine Maleate | 3 | 1999 | 176 | 0.090 |
Why?
|
| Review Literature as Topic | 1 | 2012 | 336 | 0.090 |
Why?
|
| Mice, Mutant Strains | 2 | 2004 | 1866 | 0.090 |
Why?
|
| Accidents, Traffic | 1 | 2015 | 819 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 8628 | 0.090 |
Why?
|
| Diazepam | 3 | 1999 | 205 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 1770 | 0.090 |
Why?
|
| Cause of Death | 1 | 2020 | 3584 | 0.090 |
Why?
|
| Hypogonadism | 1 | 2015 | 798 | 0.090 |
Why?
|
| Energy Metabolism | 2 | 1999 | 2895 | 0.080 |
Why?
|
| Pyridines | 1 | 2021 | 2822 | 0.080 |
Why?
|
| Muscle Weakness | 1 | 2011 | 415 | 0.080 |
Why?
|
| GABA Modulators | 2 | 1999 | 107 | 0.080 |
Why?
|
| Propranolol | 3 | 1999 | 502 | 0.080 |
Why?
|
| Nose | 1 | 2012 | 509 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2004 | 6274 | 0.080 |
Why?
|
| Hyperplasia | 1 | 2011 | 1184 | 0.080 |
Why?
|
| Insulin Resistance | 2 | 2001 | 3863 | 0.080 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 13668 | 0.080 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 39045 | 0.080 |
Why?
|
| Gestational Age | 1 | 2016 | 3493 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 3474 | 0.080 |
Why?
|
| Contrast Media | 1 | 2001 | 5300 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2020 | 4553 | 0.080 |
Why?
|
| Hippocampus | 2 | 1999 | 3676 | 0.070 |
Why?
|
| In Situ Hybridization | 2 | 2003 | 1950 | 0.070 |
Why?
|
| Receptors, Ghrelin | 1 | 2006 | 25 | 0.070 |
Why?
|
| Blood Glucose | 3 | 2018 | 6259 | 0.070 |
Why?
|
| Heart Failure, Systolic | 1 | 2008 | 126 | 0.070 |
Why?
|
| Elasticity | 2 | 2005 | 657 | 0.070 |
Why?
|
| Rats, Wistar | 3 | 1999 | 1903 | 0.070 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 1999 | 449 | 0.070 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 5138 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 1998 | 5096 | 0.070 |
Why?
|
| Bariatric Surgery | 1 | 2015 | 952 | 0.070 |
Why?
|
| Mice | 10 | 2016 | 81178 | 0.070 |
Why?
|
| Appetite Regulation | 1 | 2006 | 88 | 0.070 |
Why?
|
| Calcitonin | 1 | 2007 | 336 | 0.070 |
Why?
|
| Rats | 7 | 2003 | 24273 | 0.070 |
Why?
|
| Pediatrics | 1 | 2020 | 3469 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 1998 | 4465 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 15070 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 11368 | 0.070 |
Why?
|
| Neurosurgical Procedures | 2 | 2016 | 2003 | 0.060 |
Why?
|
| Cardiac Output | 1 | 2008 | 854 | 0.060 |
Why?
|
| Quinazolines | 1 | 2012 | 1356 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2001 | 4252 | 0.060 |
Why?
|
| Vascular Resistance | 1 | 2008 | 937 | 0.060 |
Why?
|
| Mice, Knockout | 4 | 2004 | 14556 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2018 | 53280 | 0.060 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 57768 | 0.060 |
Why?
|
| Gastrointestinal Motility | 1 | 2006 | 225 | 0.060 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2006 | 235 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 5442 | 0.060 |
Why?
|
| Infant, Newborn | 3 | 2022 | 25618 | 0.060 |
Why?
|
| Heart Failure | 1 | 2008 | 10905 | 0.060 |
Why?
|
| Spine | 1 | 2011 | 1145 | 0.060 |
Why?
|
| Recurrence | 1 | 2015 | 8343 | 0.060 |
Why?
|
| Drug Implants | 1 | 2004 | 243 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 13990 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 6 | 2004 | 21824 | 0.060 |
Why?
|
| Body Composition | 2 | 2012 | 2400 | 0.060 |
Why?
|
| Mice, Obese | 1 | 2004 | 424 | 0.060 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 1999 | 1240 | 0.060 |
Why?
|
| Gastric Mucosa | 1 | 2006 | 599 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2003 | 12207 | 0.060 |
Why?
|
| Chemokine CCL4 | 1 | 2002 | 128 | 0.050 |
Why?
|
| Stroke Volume | 2 | 2008 | 5008 | 0.050 |
Why?
|
| Delayed-Action Preparations | 2 | 2016 | 964 | 0.050 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2002 | 122 | 0.050 |
Why?
|
| Seizures | 1 | 2015 | 2859 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 14726 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2003 | 8302 | 0.050 |
Why?
|
| Sex Factors | 3 | 2014 | 10396 | 0.050 |
Why?
|
| Aldosterone | 1 | 2007 | 877 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3132 | 0.050 |
Why?
|
| Calcium | 2 | 2014 | 5757 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3239 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2003 | 520 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2007 | 1094 | 0.050 |
Why?
|
| Vitamin D | 2 | 2014 | 3222 | 0.050 |
Why?
|
| Neurons | 1 | 2001 | 9335 | 0.050 |
Why?
|
| Thyroidectomy | 1 | 2007 | 879 | 0.050 |
Why?
|
| Pregnancy | 1 | 2023 | 29142 | 0.050 |
Why?
|
| Oxygen Consumption | 1 | 2008 | 1869 | 0.050 |
Why?
|
| Placebos | 1 | 2005 | 1677 | 0.050 |
Why?
|
| Acute Disease | 2 | 2003 | 7148 | 0.050 |
Why?
|
| Brain | 3 | 2003 | 26413 | 0.050 |
Why?
|
| Swimming | 2 | 1998 | 206 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2011 | 2586 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 3703 | 0.050 |
Why?
|
| Cardiovascular Diseases | 3 | 2022 | 15161 | 0.050 |
Why?
|
| Lipid Metabolism Disorders | 1 | 2020 | 19 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2005 | 2032 | 0.050 |
Why?
|
| Cerebral Cortex | 2 | 2015 | 5709 | 0.050 |
Why?
|
| Hepatic Artery | 1 | 2001 | 242 | 0.040 |
Why?
|
| Ventricular Function, Right | 1 | 2004 | 592 | 0.040 |
Why?
|
| Aorta, Abdominal | 1 | 2003 | 645 | 0.040 |
Why?
|
| Species Specificity | 1 | 2004 | 2480 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2004 | 689 | 0.040 |
Why?
|
| Arginine Vasopressin | 1 | 2019 | 130 | 0.040 |
Why?
|
| Flumazenil | 1 | 1999 | 85 | 0.040 |
Why?
|
| Japan | 1 | 2003 | 1361 | 0.040 |
Why?
|
| Appetite Stimulants | 1 | 1998 | 13 | 0.040 |
Why?
|
| Finite Element Analysis | 1 | 2021 | 431 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 1999 | 424 | 0.040 |
Why?
|
| Injections, Intraventricular | 1 | 1998 | 230 | 0.040 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2006 | 1221 | 0.040 |
Why?
|
| Intracranial Aneurysm | 1 | 2008 | 1197 | 0.040 |
Why?
|
| RNA, Antisense | 1 | 1998 | 138 | 0.040 |
Why?
|
| Chemokines | 1 | 2002 | 969 | 0.040 |
Why?
|
| Triiodothyronine | 1 | 2020 | 494 | 0.040 |
Why?
|
| Appetite Depressants | 1 | 1998 | 110 | 0.040 |
Why?
|
| Therapeutics | 1 | 1998 | 116 | 0.040 |
Why?
|
| Pro-Opiomelanocortin | 1 | 1998 | 163 | 0.040 |
Why?
|
| Neonatal Screening | 1 | 2022 | 591 | 0.040 |
Why?
|
| Glucagon-Like Peptides | 1 | 1998 | 127 | 0.040 |
Why?
|
| Autoradiography | 1 | 1998 | 749 | 0.040 |
Why?
|
| Penile Erection | 1 | 1998 | 97 | 0.040 |
Why?
|
| Gonadotropins | 1 | 1998 | 241 | 0.040 |
Why?
|
| Radiation | 1 | 1997 | 49 | 0.040 |
Why?
|
| Immobilization | 1 | 1998 | 236 | 0.040 |
Why?
|
| Thyroid Hormones | 1 | 2020 | 390 | 0.040 |
Why?
|
| Blotting, Northern | 1 | 1999 | 1581 | 0.040 |
Why?
|
| Chromatography, Gel | 1 | 1998 | 668 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 9275 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2020 | 40559 | 0.040 |
Why?
|
| Genes, fos | 1 | 1997 | 183 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2021 | 1676 | 0.040 |
Why?
|
| Postmenopause | 1 | 2005 | 2461 | 0.040 |
Why?
|
| Aorta, Thoracic | 1 | 2003 | 1082 | 0.040 |
Why?
|
| Shock, Septic | 1 | 2003 | 775 | 0.030 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 1998 | 340 | 0.030 |
Why?
|
| Temperature | 1 | 2003 | 2206 | 0.030 |
Why?
|
| Psychopathology | 1 | 2019 | 409 | 0.030 |
Why?
|
| Thyroxine | 1 | 2020 | 666 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2020 | 1574 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2018 | 15294 | 0.030 |
Why?
|
| Dietary Fats | 1 | 2004 | 2017 | 0.030 |
Why?
|
| Melanoma | 1 | 2014 | 5475 | 0.030 |
Why?
|
| Spinal Cord Diseases | 1 | 2019 | 299 | 0.030 |
Why?
|
| Glucose Intolerance | 1 | 2020 | 577 | 0.030 |
Why?
|
| Thyroid Nodule | 1 | 2002 | 750 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 3871 | 0.030 |
Why?
|
| Professional-Patient Relations | 1 | 2020 | 737 | 0.030 |
Why?
|
| Pituitary-Adrenal System | 1 | 1998 | 553 | 0.030 |
Why?
|
| Hypercalcemia | 1 | 1997 | 407 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 950 | 0.030 |
Why?
|
| Spinal Fractures | 1 | 2021 | 696 | 0.030 |
Why?
|
| Equipment Failure | 1 | 1997 | 579 | 0.030 |
Why?
|
| Urban Population | 2 | 1993 | 2021 | 0.030 |
Why?
|
| Receptor, Insulin | 1 | 1998 | 846 | 0.030 |
Why?
|
| Ergolines | 1 | 2014 | 61 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2020 | 1009 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2019 | 40992 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1997 | 575 | 0.030 |
Why?
|
| Kinetics | 2 | 2000 | 6474 | 0.030 |
Why?
|
| Self Report | 2 | 2016 | 3558 | 0.030 |
Why?
|
| Drug Interactions | 1 | 1998 | 1458 | 0.030 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1999 | 895 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 1049 | 0.030 |
Why?
|
| Hypophysectomy | 1 | 2013 | 113 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2004 | 3469 | 0.030 |
Why?
|
| Stress, Psychological | 2 | 1999 | 4245 | 0.030 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 5755 | 0.030 |
Why?
|
| Peripheral Vascular Diseases | 1 | 1996 | 550 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2020 | 1361 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 2886 | 0.030 |
Why?
|
| Heart Rate | 1 | 2004 | 4092 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 20123 | 0.030 |
Why?
|
| Testosterone | 2 | 2020 | 2411 | 0.030 |
Why?
|
| Syndrome | 1 | 1998 | 3250 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 1998 | 941 | 0.030 |
Why?
|
| Phenotype | 2 | 2020 | 16365 | 0.030 |
Why?
|
| Algorithms | 1 | 2012 | 13885 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2005 | 12035 | 0.030 |
Why?
|
| Down-Regulation | 1 | 1999 | 3001 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 10949 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 1477 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 1888 | 0.020 |
Why?
|
| Metabolomics | 1 | 2020 | 1483 | 0.020 |
Why?
|
| Exercise | 1 | 2008 | 5615 | 0.020 |
Why?
|
| Prevalence | 3 | 2019 | 15226 | 0.020 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2012 | 369 | 0.020 |
Why?
|
| Myocardium | 1 | 2004 | 4776 | 0.020 |
Why?
|
| Feeding Behavior | 2 | 2000 | 3188 | 0.020 |
Why?
|
| Diabetic Angiopathies | 1 | 1996 | 820 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2001 | 2916 | 0.020 |
Why?
|
| Central Nervous System | 1 | 1997 | 1357 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2013 | 769 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 12244 | 0.020 |
Why?
|
| Heart | 1 | 2003 | 4465 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2015 | 2619 | 0.020 |
Why?
|
| Brain Diseases | 1 | 2019 | 1564 | 0.020 |
Why?
|
| Patient Preference | 1 | 2016 | 887 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2020 | 2529 | 0.020 |
Why?
|
| Reference Values | 1 | 2016 | 4982 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1997 | 2234 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2002 | 9147 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2012 | 878 | 0.020 |
Why?
|
| Echocardiography | 1 | 2020 | 5103 | 0.020 |
Why?
|
| Health Status | 1 | 2020 | 4034 | 0.020 |
Why?
|
| Massachusetts | 1 | 2000 | 8663 | 0.020 |
Why?
|
| Communication | 1 | 2020 | 3749 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2012 | 1531 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 10250 | 0.020 |
Why?
|
| Weight Gain | 1 | 2015 | 2292 | 0.020 |
Why?
|
| Survival Rate | 1 | 2000 | 12781 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 1998 | 3966 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 1987 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 3614 | 0.020 |
Why?
|
| Mutation | 2 | 2020 | 29784 | 0.020 |
Why?
|
| Psychometrics | 1 | 2014 | 3002 | 0.020 |
Why?
|
| Smoking | 2 | 1998 | 8986 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 1889 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 7281 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 7723 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1997 | 3336 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1998 | 7908 | 0.010 |
Why?
|
| Greece | 2 | 1993 | 344 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 6893 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 2726 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2014 | 8321 | 0.010 |
Why?
|
| United States | 2 | 2020 | 69867 | 0.010 |
Why?
|
| Microsomes | 1 | 2000 | 257 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8387 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 2000 | 252 | 0.010 |
Why?
|
| Receptors, Leptin | 1 | 2001 | 360 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2000 | 390 | 0.010 |
Why?
|
| Hypertension | 2 | 2015 | 8480 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1998 | 226 | 0.010 |
Why?
|
| Food Deprivation | 1 | 1998 | 116 | 0.010 |
Why?
|
| Agouti-Related Protein | 1 | 1998 | 98 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 2050 | 0.010 |
Why?
|
| HIV Wasting Syndrome | 1 | 1997 | 97 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 2000 | 709 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 23337 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 8426 | 0.010 |
Why?
|
| Infant | 1 | 2019 | 35129 | 0.010 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 1997 | 331 | 0.010 |
Why?
|
| Biological Transport | 1 | 2000 | 2120 | 0.010 |
Why?
|
| Restraint, Physical | 1 | 1997 | 193 | 0.010 |
Why?
|
| Cell Line | 2 | 2000 | 15999 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 1993 | 5319 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 6367 | 0.010 |
Why?
|
| Diphosphonates | 1 | 1997 | 624 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 6313 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1997 | 2007 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1996 | 11732 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 1996 | 1092 | 0.010 |
Why?
|
| Energy Intake | 1 | 1998 | 2148 | 0.010 |
Why?
|
| Gene Deletion | 1 | 1998 | 2751 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 1997 | 1801 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2000 | 3748 | 0.010 |
Why?
|
| Body Weight | 1 | 2001 | 4666 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2003 | 4044 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 12801 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 1996 | 1814 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 13817 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2001 | 9735 | 0.000 |
Why?
|
| Triglycerides | 1 | 1996 | 2453 | 0.000 |
Why?
|
| Epithelial Cells | 1 | 2000 | 3690 | 0.000 |
Why?
|
| Linear Models | 1 | 1998 | 5953 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 18116 | 0.000 |
Why?
|
| Cholesterol | 1 | 1996 | 2911 | 0.000 |
Why?
|
| Regression Analysis | 1 | 1996 | 6461 | 0.000 |
Why?
|
| Stem Cells | 1 | 1998 | 3567 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2000 | 4033 | 0.000 |
Why?
|
| Hypoglycemic Agents | 1 | 1993 | 2875 | 0.000 |
Why?
|